India Makes Cough Syrups Prescription-Only: Drugs (Fifth Amendment) Rules 2026 Explained

Kaustav Chowdhury
1 day ago
5 min read

On June 9, 2026, the Government of India notified the Drugs (Fifth Amendment) Rules 2026 through the Gazette of India, ending the decades-old practice of selling cough syrups over the counter without a prescription. The amendment is short, surgical, and significant: it removes a single word from a schedule that had allowed pharmacies across the country to dispense cough syrups freely. For consumers, this means a visit to a doctor before purchasing what was once a routine household medicine. For pharmacies and retailers, it introduces new compliance obligations backed by serious penalties.

What Do the Drugs (Fifth Amendment) Rules 2026 Change?

The amendment targets one specific provision. It removes the word "Syrups" from item (7) under serial number 13 of Schedule K to the Drugs and Cosmetics Rules, 1945. Before this change, item (7) included syrups among drug formulations exempt from certain regulatory requirements. After the amendment, syrups are no longer listed in that exemption.

The practical consequence is straightforward: cough syrups can no longer be sold over the counter. Every purchase now requires a valid prescription from a registered medical practitioner. This applies uniformly across India, covering all pharmacies, drug retailers, and e-commerce platforms that sell pharmaceutical products. Much like recent regulatory action against online sale of hazardous chemicals, the government is tightening controls on products that pose public safety risks when sold without adequate oversight.

How Schedule K Worked Before the Amendment

To understand why removing one word matters so much, consider the role of Schedule K within India's drug regulation framework. The Drugs and Cosmetics Act, 1940, and the rules framed under it govern the manufacture, sale, and distribution of drugs in India. Chapter IV of the Act lays down requirements for the sale of drugs, including prescriptions, proper labelling, and licensed sellers.

Schedule K, however, provides a list of exemptions from Chapter IV. Drugs and formulations listed in Schedule K can be sold without complying with all the requirements that normally apply. For items under serial number 13, item (7), this exemption historically covered syrups, meaning cough syrups could be sold without a prescription. Pharmacists did not need to record these sales in the same manner as prescription drugs, and consumers could walk in and purchase them freely.

By deleting the word "Syrups" from this provision, the Fifth Amendment pulls cough syrups back under the full regulatory requirements of Chapter IV. They are now treated like any other prescription drug for the purposes of sale and dispensation.

Why Was This Change Necessary?

The amendment did not emerge in a vacuum. It was triggered by tragic incidents involving contaminated cough syrups that caused child deaths in Madhya Pradesh and Rajasthan. These fatalities drew national attention to gaps in how cough syrups were manufactured, distributed, and sold. Investigations revealed that some manufacturers had used toxic substances, including diethylene glycol and ethylene glycol, as cheaper substitutes for pharmaceutical-grade ingredients.

Because cough syrups were OTC products, they moved through the supply chain with fewer checkpoints. The Schedule K exemption meant that sales did not require the same documentation, record-keeping, or prescription verification that applies to other drugs. This made it harder for regulators to trace contaminated batches and identify affected consumers.

The government's response addresses this traceability problem directly. With a prescription requirement in place, every sale must be documented, the prescribing doctor is on record, and the supply chain becomes significantly more auditable. This mirrors a broader regulatory trend in India, where authorities are increasingly willing to impose stricter controls on products that have caused consumer harm. The IRDAI's recent directive requiring insurers to audit dark pattern compliance on online platforms reflects the same philosophy: when consumer safety is at stake, regulators will tighten the rules.

Impact on Pharmacies, Retailers, and Consumers

The amendment's impact falls on three groups: pharmacies and drug retailers, e-commerce platforms, and consumers.

For pharmacies and drug retailers, the change introduces immediate operational requirements. They must now verify a valid prescription before dispensing any cough syrup. Sales records must document the prescribing doctor's details, the patient's name, and the quantity dispensed. Retailers who are not licensed to sell prescription drugs, such as general stores in rural areas that may have stocked cough syrups alongside other household products, can no longer carry these items at all. Any business involved in retail drug sales should ensure its trade licence and municipal approvals remain current and aligned with the updated regulatory requirements.

For e-commerce platforms, the compliance burden is arguably greater. Online pharmacies must implement prescription upload and verification mechanisms before processing cough syrup orders. Platforms that previously listed cough syrups in their OTC categories will need to reclassify them. Given the scrutiny digital platforms already face, non-compliance could attract heightened enforcement action.

For consumers, the change adds an extra step to purchasing a common medicine. While this may cause short-term inconvenience, particularly in areas with limited access to doctors, the prescription requirement is designed to ensure that a medical professional evaluates the patient's condition before a cough syrup is dispensed. This is especially important for children, who were the primary victims of the contaminated syrup incidents.

Compliance Obligations and Penalties

Since cough syrups now fall under the full scope of Chapter IV, selling them without a prescription constitutes a violation of the Drugs and Cosmetics Act, 1940. The penalties are significant. Under Section 27, a first offence can attract imprisonment up to three years, a fine, or both. For subsequent offences, the penalties are more severe.

Drug inspectors now have the authority to inspect pharmacies and retail outlets for compliance with the new prescription requirement. Retailers should expect increased inspections in the initial months following the notification, as regulators typically step up enforcement during transition periods.

Pharmacies should take immediate steps: update standard operating procedures to include cough syrups in the prescription-only category, train staff on the new requirement, adjust inventory systems to flag cough syrups as prescription drugs, and ensure record-keeping practices comply with Chapter IV documentation requirements.

Key Takeaways

1. Prescription now mandatory: The Drugs (Fifth Amendment) Rules 2026, notified on June 9, 2026, remove the word "Syrups" from Schedule K, ending the OTC exemption for cough syrups across India.

2. Triggered by safety failures: The amendment was prompted by child deaths from contaminated cough syrups in Madhya Pradesh and Rajasthan, exposing critical gaps in the existing regulatory framework.

3. Full Chapter IV compliance required: Cough syrups now fall under the complete regulatory requirements of Chapter IV of the Drugs and Cosmetics Act, 1940, including prescription verification and detailed record-keeping.

4. Pharmacies and e-commerce platforms must act now: Retailers must update SOPs, reclassify cough syrups in their systems, and train staff. Online pharmacies must implement prescription upload and verification workflows.

5. Penalties are serious: Selling cough syrups without a prescription now violates the Drugs and Cosmetics Act. First offences can result in imprisonment up to three years, fines, or both, with harsher penalties for repeat violations.